AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Other Events
Item 9.01 Other Events.
On April 8, 2019, Audentes Therapeutics, Inc. issued a press release announcing the expansion of its scientific platform and pipeline to advance vectorized antisense treatments for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits.
Audentes Therapeutics, Inc. Exhibit
EX-99.1 2 bold-ex991_6.htm EX-99.1 bold-ex991_6.htm Exhibit 99.1 Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy – Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) – Exclusive license agreement with the Research Institute at Nationwide Children’s Hospital to develop first product candidate,…
To view the full exhibit click
About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.